Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
Poulam M. Patel(Nottingham University Hospitals NHS Trust), Alan Spatz(Jewish General Hospital), John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Dirk Schadendorf(National Center for Tumor Diseases), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Cornelis J.A. Punt(Utrecht University), Alexander M.M. Eggermont(University Medical Center Utrecht), Sanjiv S. Agarwala(Goethe University Frankfurt), Kristel Engelen(European Organisation for Research and Treatment of Cancer), Ulrich Keilholz(German Cancer Research Center), Robert M. Conry(University of Alabama), Laurent Mortier, Stefan Suciu(St James's University Hospital), Reinhard Dummer(University Hospital of Zurich), Caroline Robert(Institut Gustave Roussy), Neville Davidson(Broomfield Hospital), Juergen C. Becker(Centre Hospitalier Universitaire Brugmann), Wim H.J. Kruit(Erasmus MC), Uwe Trefzer(Goethe University Frankfurt)
Cited by 210
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k